Clinical trials: SARS CoV 2 Infection
COVID-19
Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients.
- Trial name
- NCT05675748
- Testing
- Azvudine
- Volunteers
- 400 people
- Sponsor
- Shanghai Henlius Biotech
Coronavirus
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.
- Trial name
- EQUINOX (NCT04605926)
- Testing
- EQ001
- Where
- Colombia
- Sponsor
- Biocon Limited
COVID-19, Asymptomatic COVID-19
A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test
To determine the accuracy of Proof Diagnostics COVID-19 Test in the intended, symptomatic and suspected/at-risk asymptomatic population and point-of-care use as compared to a standard molecular comparator, Quidel Lyra SARS-CoV-2…
- Trial name
- NCT05331976
- Testing
- Proof Lab Test System
- Where
- 3 sites in United States
- Volunteers
- 276 people
- Sponsor
- Proof Diagnostics
COVID-19 Vaccine
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
The purpose of this study is to assess the safety, tolerability, and immunogenicity of booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT05197153
- Testing
- Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222
- Where
- 4 sites in Taiwan
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
COVID-19 Prevention
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
- Trial name
- NCT04908722
- Testing
- Ad26.COV2.S
- Where
- 43 sites in United States, Brazil and 3 more
- Volunteers
- 1,609 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Coronavirus Infection, Severe Acute Respiratory Infection
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive…
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NATADEX (NCT04452565)
- Testing
- Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone
- Where
- 31 sites in United States
- Volunteers
- 525 people
- Sponsor
- Biomed Industries, Inc.
COVID-19
Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
- Trial name
- NCT04479644
- Testing
- BRII-198
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Covid-19
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
- Trial name
- NCT04523181
- Testing
- Antroquinonol
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 124 people
- Sponsor
- Golden Biotechnology Corporation
Healthy
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants.
- Trial name
- NCT04590430
- Testing
- HFB30132A
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HiFiBiO Therapeutics
COVID-19, Coronavirus Infection
Study to Evaluate the Effect of a Probiotic in COVID-19
A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients…
- Trial name
- NCT04390477
- Testing
- Probiotic
- Where
- 2 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Bioithas SL
Coronavirus Disease 2019
Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19
This is a clinical trial to evaluate the safety, PK, viral shedding and clinical effects of Pentarlandir™ UPPTA in patients with early COVID-19.
- Trial name
- NCT04911777
- Testing
- Pentarlandir™ UPPTA
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Covid19
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment.
- Trial name
- NCT06012565
- Testing
- KAND567, Microcrystalline cellulose
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 35 people
- Sponsor
- Novakand Pharma AB
COVID-19
Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults
Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a recombinant protein vaccine, for the prevention of COVID-19 in healthy adults
- Trial name
- NCT04783311
- Testing
- EuCorVac-19, Normal Saline
- Where
- South Korea
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
COVID-19
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of DXP604 in patients with mild to moderate COVID-19.
- Trial name
- NCT05381519
- Testing
- DXP604
- Volunteers
- 50 people
- Sponsor
- Wuhan Institute of Biological Products Co., Ltd
COVID-19, SARS-CoV-2
Secondary Databased Post-marketing Surveillance Study of BNT162b2
This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.
- Trial name
- NCT06743334
- Testing
- Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
- Where
- South Korea
- Volunteers
- 14,302,529 people
- Sponsor
- Pfizer
COVID-19, SARS-CoV 2
Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19
There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has significant anti-inflammatory and antioxidant properties and it lacks of side-effects.
- Conditions
- COVID-19, SARS-CoV 2, Coronavirus Infection
- Trial name
- MELCOVID (NCT04568863)
- Testing
- Melatonin intravenous
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Pharmamel S.L.
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Covid19
A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).
- Trial name
- NCT04880161
- Testing
- Ampion
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ampio Pharmaceuticals. Inc.
Covid19, Corona Virus Infection
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and…
- Conditions
- Covid19, Corona Virus Infection, Autoimmune Diseases, Coagulation Disorder, Blood
- Trial name
- NCT04818970
- Testing
- Narrow Band ultraviolet B-Band Light, non Narrow Band ultraviolet B-Band Light
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cytokind, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.